Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Receivables - Accured (2023 - 2024)

Historic Receivables - Accured for Century Therapeutics (IPSC) over the last 2 years, with Q4 2024 value amounting to $1.3 million.

  • Century Therapeutics' Receivables - Accured fell 2012.74% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year decrease of 2012.74%. This contributed to the annual value of $1.3 million for FY2024, which is 2012.74% down from last year.
  • As of Q4 2024, Century Therapeutics' Receivables - Accured stood at $1.3 million, which was down 2012.74% from $1.6 million recorded in Q4 2023.
  • Century Therapeutics' Receivables - Accured's 5-year high stood at $1.6 million during Q4 2023, with a 5-year trough of $855000.0 in Q1 2023.